R 170591Alternative Names: JNJ-2408068
Latest Information Update: 03 Oct 2007
At a glance
- Originator Janssen L.P.
- Class Antivirals
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Respiratory syncytial virus infections
Most Recent Events
- 03 Oct 2005 Discontinued - Preclinical for Respiratory syncytial virus infections in Belgium (Inhalation)
- 05 May 2001 A preclinical study has been added to the Viral Infections antimicrobial activity and pharmacodynamics sections and the pharmacokinetics section
- 05 May 2001 Preclinical development for Respiratory syncytial virus infections in Belgium (Inhalation)